Mounjaro®
Starting from £179.99/mo
Start journey Learn morePeople with thyroid conditions can, in many cases, use GLP-1 weight loss injections safely, but the answer depends on the specific thyroid diagnosis, current medication, and how well the condition is controlled. Thyroid disease and weight gain are closely linked, and it is a question our prescribers hear regularly. Mounjaro (tirzepatide) and Wegovy (semaglutide) are both licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition, and thyroid disease does not automatically rule either out. What matters is the full clinical picture: the type of thyroid condition, whether thyroid hormone levels are stable, and what other medicines you take. These are prescription-only medicines, so a prescriber assesses suitability individually before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most clinically significant restriction concerns medullary thyroid carcinoma. Both Mounjaro and Wegovy are contraindicated for anyone with a personal or family history of MTC, or with MEN2. This is a firm line based on rodent study findings, and no prescriber should move past it regardless of how compelling the weight-management case appears. If this applies to you, the conversation with a specialist begins there, not with a weight-loss clinic.
For the far more common thyroid presentations — an underactive thyroid (hypothyroidism, most often Hashimoto's thyroiditis) or an overactive one (hyperthyroidism or Graves' disease) — the picture is more nuanced. Neither condition is listed as a contraindication in the Mounjaro or Wegovy Summary of Product Characteristics. What matters clinically is whether the condition is adequately treated and stable. A prescriber reviewing a weight loss injection request for a thyroid patient will want to know that thyroid-stimulating hormone (TSH) sits within a reasonable range, not that thyroid disease exists at all. You can read the clinical detail on the licensed medicines at the NHS tirzepatide medicines page.
Untreated or poorly controlled hypothyroidism can itself cause weight gain that resists diet and activity changes, and the right first step there is optimising levothyroxine, not adding a GLP-1 injection. A GP or endocrinologist is best placed to confirm that your thyroid is well managed before a weight-loss prescription is considered.
Levothyroxine is sensitive to absorption timing, which is why the standard instruction is to take it on an empty stomach, first thing, and wait before eating. GLP-1 receptor agonists slow gastric emptying, which is part of how they reduce appetite. That slowing can theoretically affect how quickly levothyroxine moves through the gut and reaches the bloodstream, though the clinical evidence base on this specific interaction remains limited.
The NHS England guidance on weight management injections recommends discussing all current medicines with your prescriber before starting. If you take levothyroxine, your GP should know you are starting a GLP-1 injection, and it is worth agreeing how thyroid function tests will be monitored going forward. For those taking oral contraceptives alongside thyroid medication, there is a separate consideration with tirzepatide specifically: the guidance recommends adding a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. NHS England's weight management injections guidance covers this and other drug-interaction points clearly.
Our page specifically on weight loss injections and thyroid conditions goes deeper on the interaction evidence if you want more detail before your consultation. Short answer: it is a consideration to flag, not a reason to stop.
This is the part that catches people out. Levothyroxine dose is partly based on body weight. As someone loses a meaningful amount of weight on a GLP-1 medicine, their dose may need adjusting downward. If it is not reviewed, signs of over-treatment can appear: heart palpitations, disturbed sleep, feeling wired or anxious. None of those are dangerous in the short term, but they are worth catching early.
The practical implication is straightforward. Before starting treatment, tell your GP that you are planning to use a weight-loss injection. Agree a plan for when to recheck thyroid function, typically after the first significant weight loss milestone, and again if you increase your dose. If you are working with an endocrinologist, loop them in too. Our dedicated page on weight loss injections with an underactive thyroid has more on managing this in practice, and our page on weight loss injections and thyroid issues covers the broader range of thyroid presentations in detail.
Weight loss that changes thyroid requirements is a good problem, in one sense. It means treatment is working. The monitoring piece just needs to be in place from the start, and a good prescriber will ask about it. If you are thinking about where to start and want a clearer sense of which weight loss injections are available in the UK, that page sets out the licensed options side by side.
When you complete a consultation with us, a GPhC-registered Independent Prescriber reads your answers (a real clinician, not automated software) and your thyroid history forms part of that review. If MTC or MEN2 is in your background, a prescriber will not issue a prescription, and our page on weight loss injections and thyroid cancer sets out why that restriction exists and what the evidence behind it says. If you have hypothyroidism or hyperthyroidism that is stable and treated, the conversation moves to the broader clinical picture: your BMI, your other health conditions, your medicines list.
If you order before midday on a working day, a prescriber reviews your consultation the same day, and once approved, your treatment is dispatched that afternoon for free next-working-day delivery via DPD. If payday falls mid-week and that is when you are ready to order, Monday to Friday before 12pm gets you the fastest turnaround. Mounjaro and Wegovy are the two injections we dispense, both sourced through the licensed UK supply chain. Our clinical team oversees prescribing standards across every consultation, including for patients managing conditions such as heart disease, where you can find further reading on our page about weight loss injections for heart patients. There are no subscriptions; every repeat order is reviewed clinically before it is sent.
If you have questions before you start, our FAQs cover common situations including medication interactions. Or you can reach us through the contact page if you would prefer to ask directly. When you are ready, start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.